Drugs / MultiPepT1De
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02620332 | Oct 2015 → Jul 2017 | type 1 diabetes mellitus | King's College London | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MultiPepT1De | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02620332 ↗ |
| Action | Restore | “immunotherapy with MHC-selective, autoantigenic peptides restores immune tolerance” PMID 35073398 ↗ Apr 2022 |
| Modality | Peptide | “a mixture of six HLA-DRB1*0401-selective, β-cell peptides” PMID 35073398 ↗ Apr 2022 |